1 | AT-home natalizumab treated MS patient | - | - | - | - | [1] 13 13 💬
|
2 | Dosing interruption OF natalizumab | - | - | - | - | [1] 13 13 💬
|
3 | Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab | - | - | - | - | [1] 13 13 💬
|
4 | Natalizumab | [1] Natalizumab Natalizumab (Natalizumab) | [1] Natalizumab
Natalizumab
(Natalizumab, Natalizumab) 💬
| [1] ITGA4 ITGA4 💬
| [15] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | [5] 13 13, 15, 25, 46, 96 💬
|
5 | Natalizumab 300 MG IN 15 ML injection | [1] Natalizumab Natalizumab (Natalizumab) | [1] Natalizumab
Natalizumab
(Natalizumab, Natalizumab) 💬
| [1] ITGA4 ITGA4 💬
| [15] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | [1] 13 13 💬
|
6 | Natalizumab discontinuation | [1] Natalizumab Natalizumab (Natalizumab) | [1] Natalizumab
Natalizumab
(Natalizumab, Natalizumab) 💬
| [1] ITGA4 ITGA4 💬
| [15] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | [1] 13 13 💬
|
7 | Natalizumab FOR IV infusion | [1] Natalizumab Natalizumab (Natalizumab) | [1] Natalizumab
Natalizumab
(Natalizumab, Natalizumab) 💬
| [1] ITGA4 ITGA4 💬
| [15] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | [1] 13 13 💬
|
8 | Natalizumab FOR subcutaneous injection | [1] Natalizumab Natalizumab (Natalizumab) | [1] Natalizumab
Natalizumab
(Natalizumab, Natalizumab) 💬
| [1] ITGA4 ITGA4 💬
| [15] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | [1] 13 13 💬
|
9 | Natalizumab IV | [1] Natalizumab Natalizumab (Natalizumab) | [1] Natalizumab
Natalizumab
(Natalizumab, Natalizumab) 💬
| [1] ITGA4 ITGA4 💬
| [15] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | [1] 13 13 💬
|
10 | Natalizumab SC | [1] Natalizumab Natalizumab (Natalizumab) | [1] Natalizumab
Natalizumab
(Natalizumab, Natalizumab) 💬
| [1] ITGA4 ITGA4 💬
| [15] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | [1] 13 13 💬
|
11 | Natalizumab treatment | [1] Natalizumab Natalizumab (Natalizumab) | [1] Natalizumab
Natalizumab
(Natalizumab, Natalizumab) 💬
| [1] ITGA4 ITGA4 💬
| [15] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | [1] 13 13 💬
|
12 | Natalizumab/natalizumab-sztn, alemtuzumab, ocrelizumab, rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, cladribine, ofatumumab, ublituximab-xiiy, ocrelizumab and hyaluronidase-ocsq | [1] Natalizumab Natalizumab (Natalizumab) | [1] Natalizumab
Natalizumab
(Natalizumab, Natalizumab) 💬
| [1] ITGA4 ITGA4 💬
| [15] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | [1] 13 13 💬
|
13 | Personalized extended interval dosing OF natalizumab | - | - | - | - | [1] 13 13 💬
|